

**To:** Rusyn, Ivan[IRusyn@cvm.tamu.edu]; Kate Guyton[GuytonK@iarc.fr]; Martin, Matt[Martin.Matt@epa.gov]; dmreif@ncsu.edu[dmreif@ncsu.edu]  
**From:** Chiu, Weihsueh  
**Sent:** Mon 2/27/2017 1:53:40 AM  
**Subject:** Fwd: RTP-16-407R2: Final Decision

Bad news...

Regards,  
Weihsueh

=====  
Weihsueh A. Chiu, PhD  
Professor  
Texas A&M University

-- Sent from my mobile device. Please excuse terse responses.

Begin forwarded message:

**From:** "RTP (ELS)" <eesserver@eesmail.elsevier.com>  
**Date:** February 26, 2017 at 7:36:49 PM CST  
**To:** <wchiu@cvm.tamu.edu>  
**Subject:** RTP-16-407R2: Final Decision  
**Reply-To:** "RTP (ELS)" <rtp@elsevier.com>

Ms. No.: RTP-16-407R2

Title: Use of high-throughput in vitro toxicity screening data in cancer hazard evaluations  
by IARC Monograph Working Groups

Corresponding Author: Dr. Weihsueh A Chiu

Authors: Kathryn Z Guyton, PhD; Matthew T Martin, PhD; David M Reif, PhD; Ivan  
Rusyn, MD, PhD

Dear Dr. Chiu,

Thank you for submitting your manuscript to Regulatory Toxicology and Pharmacology.  
Your paper, referenced above, has been reviewed by experts in the field. The reviewer  
comments, included below, are extensive to the point of precluding just an interim revision  
of your current submission, and I regret that your manuscript cannot be accepted for  
publication as it stands.

However, there is interest in the topic you presented and you are encouraged to resubmit a  
thoroughly improved manuscript, along the recommendations offered by the reviewers. In  
this case, the new manuscript would be considered a new submission and would be given a  
new manuscript number with a new date of receipt.

Again, this critique of your paper does not imply a lack of interest in this area of research, and I hope you will continue to submit your work to this journal in the future.

Sincerely,

Dr. Gio Batta Gori, Editor-in-Chief  
Regulatory Toxicology and Pharmacology  
E-mail: [rtp@elsevier.com](mailto:rtp@elsevier.com)

Reviewers' comments: